Making top-quality cancer care accessible to all.100% free, no account required.

Finding the Best Imaging Method for Thyroid Cancer Treatment

NCT03841617 · Recruiting
About this trial

This study looks at how to measure treatment effects in patients with differentiated thyroid cancer. Researchers want to see how well a special imaging method, called 124I-PET/CT, works for patients preparing for treatment. The main goal is to compare this method under two different preparation techniques. One uses a hormone injection, and the other requires stopping hormone medications. This study will help find the best way to treat thyroid cancer.

Locations and contact

This trial is running at 1 location in the United States. It is currently recruiting.

United States1 location · 1 recruiting
  • National Institutes of Health Clinical CenterBethesda, MarylandRecruiting
Who to ask about joining
Who can join

Adults aged 18 to 90 can join this trial. It is open to both men and women with diagnosed thyroid cancer who have had surgery and still have disease. Participants should have specific conditions that show their cancer may have spread. Some patients might not be able to join, such as those who have already had treatment that didn't work or have certain serious health issues. The trial team will confirm who can participate.

What happens during the trial

Participants will receive two types of imaging tests: one after using a hormone injection and the other after stopping hormone medications. Everyone will take part in both tests. They will also receive treatment with a special radioactive iodine that helps kill cancer cells. The researchers will follow each participant's progress for five years, checking their health at regular intervals.

The trial team

The trial is sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases. Dr. Joanna Klubo-Gwiezdzinska is the principal investigator, leading the research.

Important dates

This trial started on July 29, 2019, and is expected to finish by November 1, 2035. It is currently enrolling new participants.

Additional information

The trial's ID is NCT03841617. It is a Phase 2 study, which means it is exploring how well the treatment works and how safe it is. This study is regulated by the FDA, and it aims to include 30 patients.

Similar trials

Other recruiting trials for the same condition, with the eligibility rules written in plain language.

Browse similar trials
Talk to a specialist

Find a top oncologist who can tell you whether a trial is a sensible option for you.

Find a doctor
Cancer hospitals

The cancer centers running studies like this one, and what each is known for.

Browse hospitals